two GHRH analogues, side by side
Tesamorelin vs Sermorelin: Structure and Pharmacology
Both are GHRH analogues that prompt the body's own growth hormone — but they differ in length, in stability, and in how deep the evidence runs.
The short version
Tesamorelin vs sermorelin comes down to length and stability. GHRH (the brain's own "make growth hormone" signal) is 44 amino acids long. Tesamorelin keeps the whole 44-residue chain and adds a small fatty-acid tag that stops the body from breaking it down quickly. Sermorelin is a shorter, 29-residue piece of the same signal. Both tell the pituitary to release the body's own growth hormone, but tesamorelin is the more stabilized, better-studied molecule, with two large human trials behind it. Neither is described here as something to inject; this is a structural and pharmacological comparison only.
Structure: Full-Length GHRH(1-44) vs Truncated GHRH(1-29)
The clearest difference between tesamorelin and sermorelin is chain length. Native human GHRH is a 44-amino-acid peptide. Tesamorelin is a synthetic analogue of the full-length GHRH(1-44), with a trans-3-hexenoic acid group bonded to its N-terminus [1]. Sermorelin is the truncated GHRH(1-29) — the first 29 amino acids, which carry the receptor-activating core of the molecule.
Both fragments are biologically active because the business end of GHRH sits in that N-terminal region; both bind the same GHRH receptor on pituitary somatotrophs to trigger the body's own growth-hormone release [2]. The full-length-versus-truncated distinction, plus tesamorelin's stabilizing N-terminal tag, is what separates them pharmacologically.
Stability: The DPP-IV-Resistance Difference
The functional difference follows from chemistry. Native GHRH is rapidly inactivated by DPP-IV, a protease that cleaves the peptide near its N-terminus within minutes. Tesamorelin's trans-3-hexenoic acid modification blocks that DPP-IV cleavage, extending its biological activity relative to native GHRH [1]. That stabilizing tag is the defining feature of the tesamorelin molecule and the reason it was developed.
A narrative review describes tesamorelin as a synthetic human growth-hormone-releasing-factor analogue developed because growth-hormone-releasing-factor analogues may be better tolerated than recombinant human growth hormone, summarizing Phase 3 evidence that it reduced visceral fat in HIV-related lipodystrophy with a good safety profile, while other potential indications appeared less promising [9]. The design intent was a stabilized, better-tolerated way to raise the body's own growth hormone — not a replacement for it.
Evidence Base and Regulatory Status
The two compounds differ most in how much human evidence stands behind each. Tesamorelin is FDA-approved (NDA 022505, 2010) for one indication — reducing excess abdominal fat in HIV-associated lipodystrophy — supported by two pivotal Phase 3 RCTs [3][4], a JAMA hepatic-fat trial [5], and a 2026 meta-analysis of five trials [13]. Every use outside HIV-associated lipodystrophy is off-label.
Both tesamorelin and sermorelin act through the same GHRH-receptor mechanism, and both are growth-hormone secretagogues rather than exogenous growth hormone [2][9]. Where they part company is the depth of the tesamorelin visceral-fat trial record and tesamorelin's stabilizing N-terminal modification. Both are prohibited in sport under the WADA Prohibited List as growth-hormone-axis agents. This page compares structure and pharmacology only; the full reference list carries the tesamorelin citations summarized here.